• español
    • English
    • português
  • English 
    • español
    • English
    • português
  • Login
View Item 
  •   Home
  • Productos de Investigación - Creación
  • Repositorio Documental COVID-19
  • Documentos científicos relacionados a la COVID-19
  • View Item
  •   Home
  • Productos de Investigación - Creación
  • Repositorio Documental COVID-19
  • Documentos científicos relacionados a la COVID-19
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
RecursosRecursos de apoyo¿Cómo publicar?

Browse

All of ExpeditioCommunities & CollectionsBy Issue DateAuthorsTitlesSubjects
This CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

View Usage StatisticsView Google Analytics Statistics

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

Thumbnail

Citación

       
Export: <XML METS>
View/Open
Documento reservado (1.595Mb)
Date
2020-06-05
Author
Xu, Xin
Sun, Jian
Nie, Sheng
Li, Huiyuan
Kong, Yaozhong
Liang, Min
Hou, Jinlin
Huang, Xianzhong
Li, Dongfeng
Ma, Tean
Peng, Jiaqing
Gao, Shikui
Shao, Yong
Zhu, Hong
Lau, Johnson Yiu Nam
Wang, Guangyu
Xie, Chunbao
Jiang, Li
Huang, Ailong
Yang, Zhenglin
Zhang, Kang
Hou, Fan Fan
Metadata
Show full item record
Documentos PDF
Summary in foreign language
Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5–4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5–2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection.
Palabras clave
COVID-19
URI
http://hdl.handle.net/20.500.12010/10792
Link to resource
https://www.nature.com/articles/s41591-020-0949-6#article-info
Collections
  • Documentos científicos relacionados a la COVID-19 [2292]
Comments

Respuesta Comentario Repositorio Expeditio

Gracias por tomarse el tiempo para darnos su opinión.


Carrera 4 # 22-61 Teléfono: (+57 1) 242 7030 - 018000111022 Fax: (+57 1) 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad.

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

 

Términos y condiciones | Políticas

 

 


Carrera 4 # 22-61 Teléfono: (+57 1) 242 7030 - 018000111022 Fax: (+57 1) 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad.

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

 

Términos y condiciones | Políticas